Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice

Cellular & Molecular Immunology volume 7, pages 381–388 (2010)Cite this article

Abstract

Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors that are essential for host immune responses. TLR ligands represent a promising class of immunotherapeutics or vaccine adjuvants with the potential to generate an effective antitumor immune response. The TLR7/8 agonists have aroused interest because they not only activate antigen-presenting cells but also promote activation of T and natural killer (NK) cells. However, the exact mechanism by which stimulation of these TLRs promotes immune responses remains unclear, and different TLR7/8 agonists have been found to induce different responses. In this study, we demonstrate that both gardiquimod and imiquimod promote the proliferation of murine splenocytes, stimulate the activation of splenic T, NK and natural killer T (NKT) cells, increase the cytolytic activity of splenocytes against B16 and MCA-38 tumor cell lines, and enhance the expression of costimulatory molecules and IL-12 by macrophages and bone marrow-derived dendritic cells (DCs). In a murine model, both agonists improved the antitumor effects of tumor lysate-loaded DCs, resulting in delayed growth of subcutaneous B16 melanoma tumors and suppression of pulmonary metastasis. Further, we found that gardiquimod demonstrated more potent antitumor activity than imiquimod. These results suggest that TLR7/8 agonists may serve as potent innate and adaptive immune response modifiers in tumor therapy. More importantly, they can be used as vaccine adjuvants to potentiate the efficiency of DC-based tumor immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Janeway CA Jr, Medzhitov R . Innate immune recognition. Annu Rev Immunol 2002; 20: 197–216.

    Article  CAS  Google Scholar 

  2. Uematsu S, Akira S . Toll-like receptors and innate immunity. J Mol Med 2006; 84: 712–725.

    Article  CAS  Google Scholar 

  3. Kumagai Y, Takeuchi O, Akira S . Pathogen recognition by innate receptors. J Infect Chemother 2008; 14: 86–92.

    Article  CAS  Google Scholar 

  4. Takeda K, Kaisho T, Akira . Toll-like receptors. Annu Rev Immunol 2003; 21: 335–376.

    Article  CAS  Google Scholar 

  5. Heil F, Hemmi H, Hochrein F, Ampenberger F, Kirschning C, Akira S et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004; 303: 1526–1529.

    Article  CAS  Google Scholar 

  6. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101: 5598–5603.

    Article  CAS  Google Scholar 

  7. Akira S, Uematsu S, Takeuchi O . Pathogen recognition and innate immunity. Cell 2006; 12: 4783–4801.

    Google Scholar 

  8. Wenzel J, Tormo D, Tüting T . Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects. Hand Exp Pharmacol 2008; 183: 201–220.

    Article  CAS  Google Scholar 

  9. Kaisho T, Akira S . Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med 2003; 3: 373–385.

    Article  CAS  Google Scholar 

  10. Sato A, Iwasaki A . Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. Proc Natl Acad Sci USA 2004; 101: 16274–16279.

    Article  CAS  Google Scholar 

  11. Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens ML et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42: 789–794.

    Article  CAS  Google Scholar 

  12. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM et al. The TLR7 agonist imiquimod enhances the anti–melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005; 175: 1983–1990.

    Article  CAS  Google Scholar 

  13. Smits EL, Ponsaerts P, Berneman ZN, van Tendeloo VF . The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008; 13: 859–875.

    Article  CAS  Google Scholar 

  14. Prins RM, Craft N, Bruhn KW, Khan-Farooqi HK, Koya RC, Stripecke R et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immnol 2006; 176: 157–163.

    Article  CAS  Google Scholar 

  15. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G . Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204: 1441–1451.

    Article  CAS  Google Scholar 

  16. Larangé A, Antonios D, Pallardy M, Kerdine-Römer S . TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol 2009; 85: 673–683.

    Article  Google Scholar 

  17. Caron G, Duluc D, Frémaux I, Jeannin P, David C, Gascan H et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005; 175: 1551–1557.

    Article  CAS  Google Scholar 

  18. Huang SJ, Hijnen D, Murphy GF, Kupper TS, Calarese AW, Mollet IG et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol 2009; 129: 2676–2685.

    Article  CAS  Google Scholar 

  19. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM . TLR7/8-mediated activation of human NK cell results in accessory cell-dependent IFN-gamma production. J Immunol 2005; 175: 1636–1642.

    Article  CAS  Google Scholar 

  20. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309: 1380–1384.

    Article  CAS  Google Scholar 

  21. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138–1149.

    Article  Google Scholar 

  22. Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266–1276.

    Article  Google Scholar 

  23. Marin-Esteban V, Abdul M, Charron D, Haziot A, Mooney N . Dendritic cells differentiated in the presence of a single-stranded viral RNA sequence conserved their ability to activate CD4 T lymphocytes but lose their capacity for Th1 polarization. Clin Vaccine Immunol 2008; 15: 954–962.

    Article  CAS  Google Scholar 

  24. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531–4537.

    Article  CAS  Google Scholar 

  25. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP . Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 2007; 6: 835–847.

    Article  CAS  Google Scholar 

  26. Dumitru CD, Antonysamy MA, Gorski KS, Johnson DD, Reddy LG, Lutterman JL et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother 2009; 58: 575–587.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Natural Science Foundation of China (no. 90713033), the National 973 Basic Research Program of China (no. 2007CB815800) and the National 115 Key Project for HBV Research (no. 2008ZX10002-008).

Author information

Author notes

  1. Dr C Zhang, Institute of Immunopharmacology and Immunotherapy, School of Pharmaceutical Sciences, Shandong University, 44 Wenhua West Road, Jinan 250012, China. E-mail: caizhangsd@sdu.edu.cn

Authors and Affiliations

  1. Institute of Immunopharmacology and Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan, China

    Fang Ma, Jianhua Zhang, Jian Zhang & Cai Zhang

Authors
  1. Fang Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cai Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, F., Zhang, J., Zhang, J. et al. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol 7, 381–388 (2010). https://doi.org/10.1038/cmi.2010.30

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cmi.2010.30

Keywords

This article is cited by

Search

Advanced search

Quick links